Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zidovudine intolerance.

J E Groopman1

  • 1Division of Hematology/Oncology, New England Deaconess Hospital, Boston, Massachusetts 02215.

Reviews of Infectious Diseases
|July 1, 1990
PubMed
Summary

Zidovudine can cause significant hematologic toxicity and myopathy in patients. Alternative antiviral agents with different toxicity profiles may benefit those experiencing these side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator.

British journal of pharmacology·2010
Same author

Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.

Oncogene·2009
Same author

Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo.

Oncogene·2007
Same author

Evaluation of novel cell cycle inhibitors in mantle cell lymphoma.

Oncogene·2007
Same author

Stimulation of beta 1 integrin induces tyrosine phosphorylation of vascular endothelial growth factor receptor-3 and modulates cell migration.

The Journal of biological chemistry·2001
Same author

HIV-1 Tat induces microvascular endothelial apoptosis through caspase activation.

Journal of immunology (Baltimore, Md. : 1950)·2001

Area of Science:

  • Pharmacology
  • Toxicology
  • Virology

Background:

  • Zidovudine is a key antiviral medication used in treating HIV/AIDS.
  • Hematologic toxicity, including anemia and leukopenia, is a primary concern with zidovudine therapy.
  • Myopathy is a recently identified, time-dependent adverse effect of zidovudine.

Purpose of the Study:

  • To review the toxic effects of zidovudine, focusing on hematologic and muscular toxicities.
  • To discuss management strategies for zidovudine-induced toxicities.
  • To highlight alternative antiviral agents for patients intolerant to zidovudine.

Main Methods:

  • Review of in vitro studies on zidovudine's effects on bone marrow progenitor cells.
  • Analysis of clinical manifestations of zidovudine toxicity.
  • Discussion of treatment strategies and alternative therapies.

Main Results:

  • Zidovudine significantly reduces the proliferative capacity of myeloid and erythroid precursors in vitro.
  • Clinical toxicities like anemia and leukopenia are dose- and time-dependent.
  • Myopathy, characterized by muscle weakness and elevated creatine phosphokinase, is also time-dependent.

Conclusions:

  • Hematologic and muscular toxicities are significant concerns for patients on zidovudine.
  • Hematopoietic growth factors can mitigate hematologic toxicity.
  • Alternative antivirals like dideoxyinosine offer different toxicity profiles for patient management.

Related Experiment Videos